Prevalence of SARS‐CoV‐2 infection among US blood donors by industry, May–December 2021
American Journal of Industrial Medicine · 2024
DOI: 10.1002/ajim.23552 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Industrial Medicine, 2024. Verfasst von Dallas S Shi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Field Studies and Engineering, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Cincinn…. Hauptthemen laut MEDLINE: Blood Donors, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS.
Abstract (Originalsprache)
Background
Work is a social determinant of health that is often overlooked. There are major work‐related differences in the risk of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection and death, but there have been few analyses of infection rates across industry groups. To date, only one national assessment of SARS‐CoV‐2 infection prevalence by industry based on self‐report has been completed. No study has looked at seroprevalence of COVID‐19 by industry.
Methods
During May–December 2021, blood donors with SARS‐CoV‐2 antinucleocapsid testing were sent an electronic survey about their work. Free‐text industry responses were classified using the North American Industry Classification System. We estimated seroprevalence and 95% confidence intervals (CIs) of SARS‐CoV‐2 infection by industry.
Results
Of 57,726 donors, 7040 (12%, 95% CI: 11.9%−12.5%) had prior SARS‐CoV‐2 infection. Seroprevalence was highest among Accommodation & Food Services (19.3%, 95% CI: 17.1%−21.6%), Mining, Quarrying, and Oil and Gas Extraction (19.2%, 95% CI: 12.8%−27.8%), Healthcare & Social Assistance (15.6%, 95% CI: 14.9%−16.4%), and Construction (14.7%, 95% CI: 13.1%−16.3%). Seroprevalence was lowest among Management of Companies & Enterprises (6.5%, 95% CI: 3.5%−11.5%), Professional Scientific & Technical Services (8.4%, 95% CI: 7.7%−9.0%), and Information (9.9%, 95% CI: 8.5%−11.5%).
Conclusions
While workers in all industries had serologic evidence of SARS‐CoV‐2 infection, certain sectors were disproportionately impacted. Disease surveillance systems should routinely collect work characteristics so public health and industry leaders can address health disparities using sector‐specific policies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Field Studies and Engineering, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Cincinnati, Ohio, USA.
- Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Coronaviruses and Other Respiratory Viruses Division, National Center for Immunizations and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- American Red Cross, Scientific Affairs, Rockville, Maryland, USA.
ORCID-Profile: Dallas S Shi, Matthew R Groenewold
Förderung
- Intramural CDC HHS
Zitieren
APA
Shi, D. S., McDonald, E., Shah, M., Groenewold, M. R., Haynes, J. M., Spencer, B. R., Stramer, S. L., Feldstein, L. R., Saydah, S., Jones, J., Chiu, S. K., & Rinsky, J. L. (2024). Prevalence of SARS‐CoV‐2 infection among US blood donors by industry, May–December 2021. American Journal of Industrial Medicine. https://doi.org/10.1002/ajim.23552
Vancouver
Shi DS, McDonald E, Shah M, Groenewold MR, Haynes JM, Spencer BR, et al. Prevalence of SARS‐CoV‐2 infection among US blood donors by industry, May–December 2021. American Journal of Industrial Medicine. 2024. doi:10.1002/ajim.23552
BibTeX
@article{Shi2024,
author = {Shi, Dallas S and McDonald, Emily and Shah, Melisa and Groenewold, Matthew R and Haynes, James M and Spencer, Bryan R and Stramer, Susan L and Feldstein, Leora R and Saydah, Sharon and Jones, Jefferson and Chiu, Sophia K and Rinsky, Jessica L},
title = {Prevalence of SARS‐CoV‐2 infection among US blood donors by industry, May–December 2021},
journal = {American Journal of Industrial Medicine},
year = {2024},
doi = {10.1002/ajim.23552}
}
EUVIMED